Sign in

    Steve Waite

    Research Analyst at Gilder Publishing

    Steve Waite is a Research Analyst at Gilder Publishing, focusing on emerging biotechnology firms such as Orgenesis. With a limited but targeted coverage universe, Waite has participated in earnings call analyses and provided expert insight into innovative biotech strategies. His professional background centers on publishing and research analysis within the biomedical sector, though comprehensive data on prior firms and historical timeline are limited. Details on professional credentials such as FINRA registration or industry licenses are not publicly disclosed.

    Steve Waite's questions to Orgenesis (ORGS) leadership

    Steve Waite's questions to Orgenesis (ORGS) leadership • Q4 2022

    Question

    Steve Waite of Gilder Publishing noted that centralized cell and gene therapy manufacturers appear to be struggling and asked why Orgenesis's decentralized model has a better chance of succeeding.

    Answer

    CEO Vered Caplan suggested that the struggles of centralized models are related to timing and logistics, as they require long-term planning and significant upfront capital commitments. She explained that in the current challenging financial market, Orgenesis's flexible, staged-commitment model is more attractive to customers. It allows for rapid adjustments to capacity and location, which is a significant advantage for clinical-stage companies.

    Ask Fintool Equity Research AI